drugset / Trial / NCT00442221

The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months

NCT00442221

Phase 3 Completed 500 enrolled POZEN
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of this study is to assess the safety of a single-tablet dose of Combo Formulation for the treatment of moderate to severe migraines

Timeline

Start
2004-05
Primary completion
Completion
2004-08

Drugs

EvaluationDrugModalityDoseRoute
Background Naproxen Small molecule
Background Sumatriptan Unknown

Indications